Meeting Minutes, Open Session, Drug Utilization Review Board April 21, 2021		
Drug Utilization Review Board *Due to COVID-19, this meeting was held virtually.	**DUR Board Members:** Moneeshindra Mittal, MD, Chair (Present) James Backes, PharmD, Interim Chair (Absent) Jennifer Clair, MD (Present) Katie Burenheide Foster, PharmD, MS, BCPS, FCCM (Present) Kristen Powell, PharmD (Present) LaTonyua Rice, PharmD, BCGP (Present) Arthur Snow, MD (Present) Roger Unruh DO (Present) **KDHE/DHCF/Contractor Staff:** Annette Grant, RPh. (Present) Victor Nguyen, PharmD (Present) Carol Arace, Administrative Specialist (Present) **DXC Technology Staff/KEPRO Staff** Karen Kluczykowski, RPh (Present) Kathy Kaesewurm, RN, BSN (Present) Harry Vu, PharmD (Present) Christina Faulkner, PharmD, BCPS (Present) **MCO Staff:** Bernadette Ueda, PharmD, UnitedHealthcare Community Plan (Present) Mark DeMary, PharmD, Aetna Better Health of Kansas (Present) Angie Yoo, PharmD, Sunflower State Health Plan (Present)	**Public Attendees**: Mary Shefchyk, Cheryl Donahue, Donna Birchette, Karen Malamut, Donna Osterlund, Kristin Jensen, Tracy Copeland, Sean Jones, Sara Hovland, Shawn Frohardt, Jeff Eskew, Jordan Feuerborn, Debra Scheer, Jim Baumann, Lynette Davis, Melissa Basil, Jessica Chardoulias, Laura Hill, Susie Moroney, Jomy Joseph, Samantha Williams, Rob Hansen, Gabriela Gutierrez, Connie Glock, Andrew Harsh, Brenda Mobley, Mindy Cameron, Scott Anderson, Dickerson, Kent Van De Mark, Kim Walter, Jean Ritter, Camille Kerr, Phil King, Gina Heinen, Karen Floeder (Only individuals that provided their full name are listed)

TOPIC	DISCUSSION	DECISION
I. Call to Order	Dr. Mittal called the meeting to order at 10:10 AM.	
Announcements and Introductions	The meeting operator informed every one of her role and the process for the meeting. Dr. Backes asked the state for any announcements. The State thanked Serena Stutzman, APRN, Dr. Katie Burenheide Foster, and Dr. Roger Unruh for their service to the DUR Board.	
II. Old Business **A. Review and Approval of January 20, 2021 Meeting Minutes**	**Board Discussion:** Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Snow motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.
III. New Business **A. Revised Prior Authorization (PA) Criteria** **1. Preferred Drug List**	**Background:** At the March 2021 PDL Committee meeting, the Committee reviewed and approved of the removal of the annual PA renewal from certain PDL classes. **Public Comment:** None. **Board Discussion:** The current Non-Preferred PDL renewal process was reviewed. The Board expressed appreciation for removing the annual PA requirement.	Dr. Powell motioned to approve. Dr. Rice seconded the motion. The motion was approved unanimously.
2. Duchenne Muscular Dystrophy (DMD) Agents	**Background:** This revision adds Amondys 45™ to the list of agents requiring prior authorization. **Public Comment:** Tracy Copeland, Serapta, yielded her time back to the Board. **Board Discussion:** None.	Dr. Clair motioned to approve. Dr. Unruh seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
3. Ulcerative Colitis	**Background:** This revision updates dosing guidelines for Humira® and updates the FDA's safety communication for Xeljanz®. **Public Comment:** Phil King & Gabriella Gutierrez, Pfizer, yielded their time back to the Board. Laura Hill, Abbvie, yielded her time back to the Board. **Board Discussion:** None.	Dr. Snow motioned for approval as amended. Dr. Rice seconded the motion. The motion was approved unanimously.
4. Weight Loss Agents	**Background:** This revision updates FDA-approved labeling changes for Saxenda®. **Public Comment:** Jessica Chardoulias, Novo Nordisk, yielded her time back to the Board. **Board Discussion:** None.	Dr. Powell motioned to approve. Dr. Clair seconded the motion. The motion was approved unanimously.
5. Hepatitis C Agents	**Background:** This revision removes the sobriety requirement prior to treatment. **Public Comment:** Laura Hill, Abbvie, yielded her time back to the Board. **Board Discussion:** None.	Dr. Snow motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.
III. New Business **B. New Prior Authorization (PA) Criteria** **1. Chimeric Antigen Receptor T-cell (CAR-T) Therapy Agents**	**Background:** This revision consolidates the existing criteria for Kymriah®, Tecartus® and Yescarta® and adds criteria for the new agents Abecma® and Breyanzi®. **Public Comment:**	Dr. Snow motioned to approve. Dr. Foster seconded the motion. The motion was approved unanimously

TOPIC	DISCUSSION	DECISION
	Jeff Eskew, Kite, provided some clinical information regarding Tecartus® and Yescarta®. Sara Hovland, Bristol-Meyers Squibb, yielded her time back to the Board. Susie Moroney, Novartis, yielded her time back to the Board. **Board Discussion:** None.	
2. Hypercholesterolemia Agents	**Background:** This revision includes consolidation of Juxtapid®, Praluent® and Repatha® criteria, removal of Kynamro® and addition of Evkeeza™, Nexletol™ and Nexlizet™. **Public Comment:** Scott Andersen, Regeneron, shared some clinical information on Evkeeza™. **Board Discussion:** It was clarified that agents that already had currently existing criteria would be retired once the Hypercholesterolemia takes effect.	Dr. Powell motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously
3. Consent Agenda	**Background:** This pre-management process is intended to streamline certain simple changes to certain existing PA criteria, including updates to Oncology Agents and Oncology – Auxiliary Treatment Agents. Changes to all other criteria include additions of new formulations/strengths/dosing regimens/biosimilars where the indications are the same. **Public Comment:** None. **Board Discussion:** The State requested to table this agenda item.	Dr. Snow motioned to table this item. Dr. Clair seconded the motion. The motion was approved unanimously

TOPIC	DISCUSSION	DECISION
C. Miscellaneous Items **1. Fee-for-Service Retrospective Drug Utilization Review Topic Selections**	**Background:** The DUR Board will select topics for the two (2) FFS RDUR interventions between May and July 2021. **Public Comment:** None. **Board Discussion:** The Board chose the following topics: 1) Gabapentinoids and CNS Depressants. 2) Asthma (composite of 3 sub-interventions)	Dr. Powell motioned to approve. Dr. Rice seconded the motion. The motion was approved unanimously
IV. Adjourn	The meeting adjourned at 11:34am	Dr. Unruh motioned to adjourn. Dr. Clair seconded the motion. Motion to adjourn carried unanimously

The next DUR Board meeting is scheduled for July 21, 2021.

All approved PA criteria are posted to the KDHE website- http://www.kdheks.gov/hcf/pharmacy/pa criteria.htm